全文获取类型
收费全文 | 663篇 |
免费 | 26篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 11篇 |
妇产科学 | 4篇 |
基础医学 | 45篇 |
口腔科学 | 2篇 |
临床医学 | 78篇 |
内科学 | 247篇 |
皮肤病学 | 6篇 |
神经病学 | 24篇 |
特种医学 | 22篇 |
外科学 | 111篇 |
综合类 | 2篇 |
预防医学 | 24篇 |
眼科学 | 3篇 |
药学 | 48篇 |
肿瘤学 | 62篇 |
出版年
2022年 | 5篇 |
2021年 | 17篇 |
2020年 | 8篇 |
2019年 | 10篇 |
2018年 | 14篇 |
2017年 | 2篇 |
2016年 | 5篇 |
2015年 | 6篇 |
2014年 | 15篇 |
2013年 | 23篇 |
2012年 | 36篇 |
2011年 | 34篇 |
2010年 | 17篇 |
2009年 | 15篇 |
2008年 | 43篇 |
2007年 | 33篇 |
2006年 | 38篇 |
2005年 | 39篇 |
2004年 | 34篇 |
2003年 | 26篇 |
2002年 | 30篇 |
2001年 | 18篇 |
2000年 | 25篇 |
1999年 | 21篇 |
1998年 | 7篇 |
1997年 | 8篇 |
1996年 | 5篇 |
1995年 | 4篇 |
1994年 | 5篇 |
1993年 | 5篇 |
1992年 | 12篇 |
1991年 | 13篇 |
1990年 | 14篇 |
1989年 | 9篇 |
1988年 | 14篇 |
1987年 | 14篇 |
1986年 | 8篇 |
1985年 | 12篇 |
1984年 | 12篇 |
1983年 | 4篇 |
1982年 | 5篇 |
1981年 | 2篇 |
1980年 | 3篇 |
1977年 | 4篇 |
1973年 | 2篇 |
1972年 | 2篇 |
1971年 | 3篇 |
1969年 | 3篇 |
1918年 | 1篇 |
1882年 | 1篇 |
排序方式: 共有693条查询结果,搜索用时 31 毫秒
1.
Papillary thyroid microcarcinomas (PTMs) are small tumors (< or =1 cm of diameter) that belong to the well-differentiated low-risk carcinomas of the thyroid, which are characterized by benign behavior, probably of little clinical significance, and do not affect patients' survival. They are found in otherwise normal thyroids or in multinodular goiters with a clinical frequency varying substantially according to different series. Sometimes, PTM may be associated with lymph node metastases at presentation and/or locoregional recurrences during follow-up. Distant metastases are extremely rare, but have been reported. Although deaths related to PTM are almost unknown, PTM raises therapeutic implications. This review addresses the issue of definition, treatment, and follow-up of PTM. 相似文献
2.
Iolter Cattabriga Davide Pacini Gaia Lamazza Francesco Talarico Roberto Di Bartolomeo Giovanni Grillone Letizia Bacchi-Reggiani 《European journal of cardio-thoracic surgery》2007,32(3):527-531
BACKGROUND: Nonsteroidal anti-inflammatory drugs and opioids are routinely used after cardiac surgery in order to mitigate postoperative pain; however, these drugs are burdened by side effects. Tramadol and paracetamol are believed to be lacking in such side effects. The aim of this study was to examine the efficacy of intravenous paracetamol as an adjunctive analgesic to a tramadol-based background analgesia after cardiac surgery. METHODS: A total of 113 patients participated in this single center, placebo-controlled, double-blind, randomized trial. Fifty-six patients were randomized to receive paracetamol and 57 to placebo. Intravenous study drug (1 g) was administered 15 min before the end of surgery and every 6h for 72 h. Standard analgesia (tramadol) and anti-emetic prophylactic regimen (ondansetron) were available to both patient groups. Postoperative pain was evaluated by visual analog scale, and it was measured at rest and during a deep breath. A rescue dose of 2-5 mg of intravenous morphine was administered whenever the VAS score was greater than 3. RESULTS: Baseline characteristics were equivalent between the two groups. At 12, 18, 24 h after the end of operation, patients who received paracetamol had significantly less pain at rest (p=0.0041, 0.0039, 0.0044, respectively); after this time the two groups did not differ. During a deep breath the difference was significant only at 12 h (p=0.0040). Paracetamol group required less cumulative morphine than placebo group (48 mg vs 97 mg) even if the difference did not reach statistical significance (p=0.274). CONCLUSIONS: In patients undergoing cardiac surgery, intravenous paracetamol in combination with tramadol provides effective pain control. 相似文献
3.
Davide Pacini Emmanuel Villa Sofia Martin-Suarez Roberto Di Bartolomeo 《European journal of cardio-thoracic surgery》2005,27(4):717-719
Patients who underwent isolated aortic valve replacement could come to attention for new onset aortic disease or progression of borderline alterations not corrected at the first operation, especially in the subset of bicuspid valve disease. We describe our technique in redo operations for aortic root disease, using only a vascular graft and sparing the previously implanted valve prosthesis. In case of normally functioning mechanical prosthesis, we always left the valve in situ and substituted the aortic root with a Dacron conduit, extending the replacement if necessary to the other diseased portions of the thoracic aorta. 相似文献
4.
5.
ALK Expression Defines a Distinct Group of T/Null Lymphomas (“ALK Lymphomas”) with a Wide Morphological Spectrum 下载免费PDF全文
Brunangelo Falini Barbara Bigerna Marco Fizzotti Karen Pulford Stefano A. Pileri Georges Delsol Antonino Carbone Marco Paulli Umberto Magrini Fabio Menestrina Roberto Giardini Silvana Pilotti Alessandra Mezzelani Barbara Ugolini Monia Billi Alessandra Pucciarini Roberta Pacini Pier-Giuseppe Pelicci Leonardo Flenghi 《The American journal of pathology》1998,153(3):875-886
The t(2;5)(p23;q35) translocation associated with CD30-positive anaplastic large cell lymphoma results in the production of a NPM-ALK chimeric protein, consisting of the N-terminal portion of the NPM protein joined to the entire cytoplasmic domain of the neural receptor tyrosine kinase ALK. The ALK gene products were identified in paraffin sections by using a new anti-ALK (cytoplasmic portion) monoclonal antibody (ALKc) that tends to react more strongly than a previously described ALK1 antibody with the nuclei of ALK-expressing tumor cells after microwave heating in 1 mmol/L ethylenediaminetetraacetic acid buffer, pH 8.0. The ALKc monoclonal antibody reacted selectively with 60% of anaplastic large cell lymphoma cases (60 of 100), which occurred mainly in the first three decades of life and consistently displayed a T/null phenotype. This group of ALK-positive tumors showed a wide morphological spectrum including cases with features of anaplastic large cell lymphoma “common” type (75%), “lymphohistiocytic” (10%), “small cell” (8.3%), “giant cell” (3.3%), and “Hodgkin’s like” (3.3%). CD30-positive large anaplastic cells expressing the ALK protein both in the cytoplasm and nucleus represented the dominant tumor population in the common, Hodgkin’s-like and giant cell types, but they were present at a smaller percentage (often with a perivascular distribution) also in cases with lymphohistiocytic and small cell features. In this study, the ALKc antibody also allowed us to identify small neoplastic cells (usually CD30 negative) with nucleus-restricted ALK positivity that were, by definition, more evident in the small cell variant but were also found in cases with lymphohistiocytic, common, and “Hodgkin’s-like” features. These findings, which have not been previously emphasized, strongly suggest that the neoplastic lesion (the NPM-ALK gene) must be present both in the large anaplastic and small tumor cells, and that ALK-positive lymphomas lie on a spectrum, their position being defined by the ratio of small to large neoplastic cells. Notably, about 15% of all ALK-positive lymphomas (usually of the common or giant cell variant) showed a cytoplasm-restricted ALK positivity, which suggests that the ALK gene may have fused with a partner(s) other than NPM. From a diagnostic point of view, detection of the ALK protein was useful in distinguishing anaplastic large cell lymphoma cases of lymphohistiocytic and small cell variants from reactive conditions and other peripheral T-cell lymphoma subtypes, as well as for detecting a small number of tumor cells in lymphohemopoietic tissues. In conclusion, ALK positivity appears to define a clinicopathological entity with a T/null phenotype (“ALK lymphomas”), but one that shows a wider spectrum of morphological patterns than has been appreciated in the past. 相似文献
6.
PG-M1: A New Monoclonal Antibody Directed against a Fixative-Resistant Epitope on the Macrophage-Restricted Form of the CD68 Molecule 总被引:9,自引:6,他引:9 下载免费PDF全文
Brunangelo Falini Leonardo Flenghi Stefano Pileri Marcello Gambacorta Barbara Bigerna Horst Durkop Florian Eitelbach Juergen Thiele Roberta Pacini Antonio Cavaliere Massimo Martelli Nadia Cardarelli Elena Sabattini Simonetta Poggi Harald Stein 《The American journal of pathology》1993,142(5):1359-1372
A new anti-macrophage monoclonal antibody (PG-M1) was produced by immunizing BALB/c mice with fresh spleen cells from a patient with Gaucher's disease. PG-M1 reacts strongly with a fixative-resistant epitope of an intracytoplasmic molecule, selectively expressed by virtually all macrophages of the human body. Although attempts to immunoprecipitate the molecule recognized by PG-M1 have failed so far, the reactivity of the antibody with COS-1 and WOP cells transfected with a human complementary DNA clone encoding for the CD68 antigen suggests that PG-M1 is a new member of the CD68 cluster. However, unlike other CD68 antibodies (KP1, EBM11, etc.), which react with both macrophages and myeloid cells, PG-M1 detects a fixative-resistant epitope on the macrophage-restricted form of the CD68 antigen. In 957 routinely fixed, paraffin-embedded samples, PG-M1 showed a more restricted reactivity with elements of the monocyte/macrophage lineage than the previously described monoclonal antibodies MAC-387 (anti-calgranulins), KP1 (CD68) and Ki-M1P. Among hematological malignancies, PG-M1 only labels acute leukemias of M4 and M5 type and rare examples of malignant histiocytosis/true histiocytic sarcoma. In contrast, acute leukemias of the M1, M2, M3, M6, M7, and L1-L3 types, non-Hodgkin's lymphomas, and Hodgkin and Reed-Sternberg cells of Hodgkin's disease are consistently PG-M1-negative. In the daily diagnostic practice, PG-M1 seems to be particularly valuable for the diagnosis of myelomonocytic or monocytic leukemia and neoplasms of true histiocytic origin in routine paraffin sections. 相似文献
7.
Delrio AN Sgambati E Brizzi E Pacini P Pacini S Ruggiero M Gulisano M 《Italian journal of anatomy and embryology = Archivio italiano di anatomia ed embriologia》1999,104(1):33-45
The distribution and the characteristics of A and B synoviocytes were investigated using scanning and transmission electron microscopy in the study of the three types of synovial membranes (fibrous, areolar, adipose) of the rabbit knee joint. The scanning electron microscope showed that the B-synoviocytes had dendritic processes and were separated by wide spaces in the fibrous synovium. The areolar synovium was covered by numerous B-synoviocytes of fibroblastoid-shape. The B-synoviocytes of the adipose synovium were characterized by short cytoplasmic processes. The transmission electron microscope revealed that the B-cells showed signs of intense synthetic activity such as the presence of an evident rough endoplasmic reticulum, the Golgi apparatus and many peripheric vesicles. Our study also revealed that cells with morphological and ultrastructural characteristics of macrophages, the so-called A-synoviocytes, were present in the areolar membrane. We concluded that B-synoviocytes can show variable shape under normal conditions: in particular, dendritic morphology seems to be a normal characteristic of the synoviocytes of the fibrous membrane. Moreover, our results demonstrate that A and B synoviocytes are ultrastructurally and morphologically distinct cells and that each type has different functions. 相似文献
8.
Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonist 总被引:5,自引:0,他引:5
I Setnikar M Bani R Cereda R Chisté F Makovec M A Pacini L Revel L C Rovati L A Rovati 《Arzneimittel-Forschung》1987,37(6):703-707
D,L-4-(3,4-Dichloro-benzoylamino)-5-(N-3-methoxypropyl- pentylamino)-5-oxo-pentanoic acid (CR 1505) belongs to a newly discovered class of agents with cholecystokinin (CCK) antagonistic activity. CR 1505 displaces CCK-8 from the central CCK receptors at concentrations of 9.1 mumol/l, and from the peripheral CCK receptors at concentrations of 0.33 mumol/l. CR 1505 antagonizes in vitro the contractant effects of CCK-8 on gall bladder strips of the guinea pig at 0.79 mumol/l and those on the small intestine at 1.6 mumol/l. These antagonistic effects are dose dependent and of competitive type. The antagonistic activities of CR 1505 against contractions of smooth muscles elicited by CCK-8 are at least 1000 times more potent than those against the contractions elicited by acetylcholine, BaCl2, histamine, serotonin, Substance P, bradykinin or dimethylphenylpiperazine. CR 1505 is also practically ineffective against the contractions of the small intestine of the guinea pig elicited by electrical field stimulations either as "cholinergic twich" (0.05 Hz), or as "cholinergic contractions" (trains of 10 min at 1 Hz), or as "non-cholinergic contractions" (200 impulses at 5 Hz in presence of atropine). CR 1505 is therefore a potent, specific, competitive and reversible CCK antagonist. 相似文献
9.
10.
Antonio Loforte Mariafrancesca Fiorentino Giacomo Murana Gregorio Gliozzi Giulio Giovanni Cavalli Carlo Mariani Sofia Martin Suarez Davide Pacini 《Transplantation proceedings》2021,53(1):311-317
BackgroundThe occurrence of early graft failure (EGF) after heart transplantation (Htx) often requires a mechanical circulatory support (MCS) therapy. The aims of our study were to identify risk factors of mechanically supported severe EGF and evaluate their impact on both early and late outcomes.MethodsBetween January 2000 and December 2019, 499 consecutive adult patients underwent Htx at our institution. Severe EGF was defined as the need for extracorporeal life support (ECLS) within 24 hours after surgery. All available recipient and donor variables were retrospectively analyzed.ResultsOverall, EGF occurred in 58 (11.6%) patients. Post-Htx peripheral or central ECLS was necessary in 32 (6.4%) cases. Independent predictors of severe EGF were, in the recipient group, preoperative transpulmonary gradient (TPG) >12 mm Hg (odds ratio [OR] 4.1, P = .013), preoperative inotropic score >10 (OR 7.3, P = .0001), and pre-Htx ECLS support (OR 5.2, P = .015), while in the donors, a Eurotransplant donor score ≥17 (OR 8.5, P = .005). The absence of EGF was related with a better survival at 1 year and 5 years (94% and 85%, respectively) compared with EGF requiring ECLS population (36% and 28% at 1 year and 5 years, respectively; P < .001). A five-year conditional survival rate did not differ significantly (85% no EGF vs 83% EGF requiring ECLS).ConclusionBoth donor and recipient factors may influence EGF occurrence. Post-Htx ECLS may impact negatively early; however, patients weaned from ECLS eventually benefit from such a rescue treatment with outcomes comparable with Htx patients who did not suffer EGF. 相似文献